2020

04.06.2020 – Polyphor AG

Polyphor shareholders approve all proposals at the Annual General Meeting 2020

Polyphor AG / Key word(s): AGMEGM
Polyphor shareholders approve all proposals at the Annual General Meeting
2020

04-Jun-2020 / 17:35 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Allschwil, Switzerland, June 4, 2020

Polyphor shareholders approve all proposals at the Annual General Meeting
2020

Polyphor AG (SIX: POLN) today announced that its shareholders approved all
proposals of the Board of Directors at the 23rd Annual General Meeting with
a significant majority. In line with the COVID-19 Ordinance 2 of the Swiss
Federal Council, no shareholders were allowed to attend the General Meeting
in person. The independent proxy represented 49.75 percent of the company's
shares.

"On behalf of the board of directors, I want to thank Polyphor's
shareholders for their trust and consent at today's AGM," said Kuno Sommer,
Chairman of the Board of Directors. "Polyphor thus has the flexibility to
continue the strong study progress with its phase III asset balixafortide
and to implement the renewed strategy to improve its pipeline in oncology
and novel antibiotics. We are fully aware of the duty that our shareholders
have given us today with their approval and will passionately do everything
in our power to live up to this trust for the benefit of patients and our
company."

The members of the Board of Directors, Kuno Sommer, Bernard Bollag, Silvio
Inderbitzin and Andreas Wallnöfer were re-elected for a further year in
office. In addition, the shareholders confirmed Kuno Sommer as Chairman of
the Board of Directors. Furthermore, the management report, the consolidated
financial statements, and the annual financial statements for 2019 were
approved.

In addition, the shareholders approved the renewal of authorized share
capital (up to 5'531'603 registered shares), the creation of conditional
share capital for bonds and similar debt instruments (up to 2'212'641
registered shares), the increase of conditional share capital for employee
benefit plans (by 300'000 registered shares) and the corresponding changes
to the articles of association.

AGM documents
The invitation with proposals and explanations on the agenda items is
available on the Company's website at
www.polyphor.com/investor-relations/corporate-governance.


For further information please contact:

For Investors:
Hernan Levett
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 00
Email: IR@polyphor.com


For Media:
Stephan Feldhaus
Feldhaus & Partner GmbH
Tel: +41 79 865 92 56
Email: feldhaus@feldhaus-partner.ch


About Polyphor
Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical
company committed to discovering and developing first-in-class molecules in
oncology and antimicrobial resistance leveraging the company's leading
macrocyclic peptide technology platform. Polyphor is advancing balixafortide
(POL6326) in a Phase III trial in combination with eribulin in patients with
advanced breast cancer and exploring its potential in other cancer
indications. In addition, it has discovered and is developing the Outer
Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the
first new class of antibiotics in clinical development in the last 50 years
against Gram-negative bacteria. The company's lead OMPTA program is an
inhaled formulation of murepavadin for the treatment of Pseudomonas
aeruginosa infections in patients with cystic fibrosis. Polyphor is based in
Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
For more information, please visit www.polyphor.com.

Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of the Polyphor management. Known and
unknown risks, uncertainties, and other factors could lead to material
differences between the forward-looking statements made here and the actual
development, in particular Polyphor's results, financial situation, and
performance. Readers are cautioned not to put undue reliance on
forward-looking statements, which speak only of the date of this
communication. Polyphor disclaims any intention or obligation to update and
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.


---------------------------------------------------------------------------

End of ad hoc announcement

---------------------------------------------------------------------------

close